Selank

Selank (TP-7) is a synthetic heptapeptide with the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, derived by fusing the tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with a stabilizing Pro-Gly-Pro sequence. Tuftsin itself is an endogenous peptide fragment of IgG that plays a role in immune regulation and has demonstrated central nervous system activity. Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and subsequently registered in Russia as a pharmaceutical agent, making it one of a small number of peptides in this guide with any formal regulatory approval — though exclusively within Russia, and not in Western jurisdictions. Outside Russia, it is sold as a research chemical and has no approved indication in the US, EU, UK, or Australia.

The proposed mechanism of action for Selank is multifactorial. Research suggests it modulates the GABAergic system, though not via direct benzodiazepine-receptor agonism, which may explain the anxiolytic effects observed in studies without the sedation or dependency profiles associated with classical anxiolytics. Additionally, preliminary research indicates Selank influences expression of brain-derived neurotrophic factor (BDNF), which connects to its putative nootropic and mood-stabilizing effects. Studies also suggest interaction with enkephalin metabolism — specifically inhibition of enkephalin-degrading enzymes — which may prolong endogenous opioid peptide activity in the CNS. Immunomodulatory effects, likely inherited from its tuftsin lineage, include reported modulation of interleukin and interferon expression, though the clinical significance of these effects in healthy humans remains unclear.

The evidence base for Selank is meaningful by peptide-research standards but carries important caveats. Russian clinical trials, some involving hundreds of participants, have examined its use in generalized anxiety disorder, neurasthenia, and cognitive deficits associated with anxiety states. A notable trial published in Russian-language literature (Semenova et al., 2009, and related work from the Institute of Molecular Genetics) reported statistically significant reductions in anxiety scores versus placebo in patients with GAD, with tolerability described as favorable. Animal model research — primarily in rodents — supports anxiolytic, nootropic, and immunostimulatory activity. However, virtually no independent, large-scale, peer-reviewed RCTs exist in Western literature, and replication outside Russian institutional contexts is minimal. User self-reports on English-language forums describe effects consistent with mild anxiolysis, improved verbal fluency, and mood stabilization, with a common observation that effects feel 'cleaner' than benzodiazepines. These anecdotal reports are not clinical evidence and should be interpreted accordingly.

Dosing ranges reported in published Russian research contexts — not a recommendation for human use — typically fall between 250 mcg and 3,000 mcg per day, most commonly administered intranasally in the clinical literature, with some subcutaneous protocols also described. Intranasal delivery is reported to offer rapid CNS uptake given the olfactory pathway bypass of the blood-brain barrier. Research protocols in Russian trials frequently used 250–500 mcg intranasal doses two to three times daily for periods of 10–14 days. These figures are drawn from research literature and are presented for informational purposes only; they do not constitute dosing guidance or a recommendation for human use. This content is for educational purposes only.

Outside Russia, Selank occupies the research-chemical category across all major Western regulatory jurisdictions. It is not FDA-approved, MHRA-approved, EMA-approved, or TGA-listed for any human indication. Buyers sourcing from Western vendors should treat it accordingly. When evaluating vendors, a credible certificate of analysis (COA) should include HPLC purity data (ideally >98%), mass spectrometry confirmation of the correct molecular weight (MW ~751.9 g/mol for the heptapeptide), and ideally endotoxin/LAL testing if injectable use is contemplated in a research context. Vendors who cannot provide a batch-specific COA from an accredited third-party laboratory should be avoided. Lyophilized powder form is standard; reconstitution with bacteriostatic water is typical, with refrigeration of reconstituted solution advised.